Additive effects of cilnidipine, an L-/N-type calcium channel blocker, and an angiotensin II receptor blocker on reducing cardiorenal damage in Otsuka Long-Evans Tokushima Fatty rats with type 2 diabetes mellitus

References

• Santos RA Ferreira AJ Angiotensin-(1–7) and the renin-angiotensin system Curr Opin Nephrol Hypertens 2007 16 2 122 128 17293687
   PubMed Web of Science ®Google Scholar
• Simões e Silva AC Pinheiro SV Pereira RM Ferreira AJ Santos RA The therapeutic potential of angiotensin-(1–7) as a novel renin-angiotensin system mediator Mini Rev Med Chem 2006 6 5 603 609 16719835
   PubMed Web of Science ®Google Scholar
• Matsui T Tamaya K Matsumoto K Osajima Y Uezono K Kawasaki T Plasma concentrations of angiotensin metabolites in young male normotensive and mild hypertensive subjects Hypertens Res 1999 22 4 273 277 10580393
   PubMed Web of Science ®Google Scholar
• Nogueira AI Souza Santos RA Simões E Silva AC The pregnancy-induced increase of plasma angiotensin-(1–7) is blunted in gestational diabetes Regul Pept 2007 141 1–3 55 60 17291601
   PubMedGoogle Scholar
• Oudit GY Liu GC Zhong J Human recombinant ACE2 reduces the progression of diabetic nephropathy Diabetes 2010 59 2 529 538 19934006
   PubMed Web of Science ®Google Scholar
• Burns WC Velkoska E Dean R Burrell LM Thomas MC Angiotensin II mediates epithelial-to-mesenchymal transformation in tubular cells by ANG 1–7/MAS-1-dependent pathways Am J Physiol Renal Physiol 2010 299 3 F585 F593 20554647
   PubMed Web of Science ®Google Scholar
• Bindom SM Lazartigues E The sweeter side of ACE2: physiological evidence for a role in diabetes Mol Cell Endocrinol 2009 302 2 193 202 18948167
   PubMed Web of Science ®Google Scholar
• Ritz E Schmieder RE Pollock CA Renal protection in diabetes: lessons from ONTARGET Cardiovasc Diabetol 2010 9 60 20920303
   PubMed Web of Science ®Google Scholar
• Hoogwerf BJ Renin-angiotensin system blockade and cardiovascular and renal protection Am J Cardiol 2010 105 Suppl 1 30A 35A
   Google Scholar
• Bichu P Nistala R Khan A Sowers JR Whaley-Connell A Angiotensin receptor blockers for the reduction of proteinuria in diabetic patients with overt nephropathy: results from the AMADEO study Vasc Health Risk Manag 2009 5 1 129 140 19436679
   PubMedGoogle Scholar
• Levy BI How to explain the differences between renin angiotensin system modulators Am J Hypertens 2005 18 9 Pt 2 134S 141S 16125050
   PubMed Web of Science ®Google Scholar
• McMurray JJ Ostergren J Swedberg K CHARM Investigators and Committees Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial Lancet 2003 362 9386 767 771 13678869
   PubMed Web of Science ®Google Scholar
• Forclaz A Maillard M Nussberger J Brunner HR Burnier M Angiotensin II receptor blockade: is there truly a benefit of adding an ACE inhibitor? Hypertension 2003 41 1 31 36 12511526
   PubMed Web of Science ®Google Scholar
• Azizi M Ménard J Bissery A Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption J Am Soc Nephrol 2004 15 12 3126 3133 15579516
   PubMed Web of Science ®Google Scholar
• Mann JF Schmieder RE McQueen M ONTARGET investigators Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial Lancet 2008 372 9638 547 553 18707986
   PubMed Web of Science ®Google Scholar
• Parving HH Brenner BM McMurray JJ ALTITUDE Investigators Cardiorenal end points in a trial of aliskiren for type 2 diabetes N Engl J Med 2012 367 23 2204 2213 23121378
   PubMed Web of Science ®Google Scholar
• Takahara A Cilnidipine: a new generation Ca channel blocker with inhibitory action on sympathetic neurotransmitter release Cardiovasc Ther 2009 27 2 124 139 19426250
   PubMed Web of Science ®Google Scholar
• Takahara A Koganei H Takeda T Iwata S Antisympathetic and hemodynamic property of a dual L/N-type Ca(2+) channel blocker cilnidipine in rats Eur J Pharmacol 2002 434 1–2 43 47 11755164
   PubMed Web of Science ®Google Scholar
• Shiga T Yamada Y Matsuda N Influence of cilnidipine or nisoldipine on sympathetic activity in healthy male subjects Heart Vessels 2007 22 6 404 409 18043999
   PubMed Web of Science ®Google Scholar
• Nagahama S Norimatsu T Maki T Yasuda M Tanaka S The effect of combination therapy with an L/N-type Ca(2+) channel blocker, cilnidipine, and an angiotensin II receptor blocker on the blood pressure and heart rate in Japanese hypertensive patients: an observational study conducted in Japan Hypertens Res 2007 30 9 815 822 18037774
   PubMed Web of Science ®Google Scholar
• Varagic J Susic D Frohlich ED Cilnidipine improves spontaneously hypertensive rat coronary hemodynamics without altering cardiovascular mass and collagen J Hypertens 2002 20 2 317 322 11821718
   PubMed Web of Science ®Google Scholar
• Sakata K Yoshida H Tamekiyo H Comparative effect of clinidipine and quinapril on left ventricular mass in mild essential hypertension Drugs Exp Clin Res 2003 29 3 117 123 14708457
   PubMedGoogle Scholar
• Takemori K Ishida H Dote K Yamamoto K Ito H Prophylactic effects of an N- and L-type Ca2+ antagonist, cilnidipine, against cardiac hypertrophy and dysfunction in stroke-prone, spontaneously hypertensive rats Can J Physiol Pharmacol 2005 83 8–9 785 790 16333380
   PubMed Web of Science ®Google Scholar
• Nagai H Minatoguchi S Chen XH Cilnidipine, an N+L-type dihydropyridine Ca channel blocker, suppresses the occurrence of ischemia/reperfusion arrhythmia in a rabbit model of myocardial infarction Hypertens Res 2005 28 4 361 368 16138567
   PubMed Web of Science ®Google Scholar
• Fujita T Ando K Nishimura H Cilnidipine versus Amlodipine Randomized Trial for Evaluation in Renal Disease(CARTER) Study Investigators Antiproteinuric effect of the calcium channel blocker cilnidipine added to renin-angiotensin inhibition in hypertensive patients with chronic renal disease Kidney Int 2007 72 12 1543 1549 17943080
   PubMed Web of Science ®Google Scholar
• Zhou X Ono H Ono Y Frohlich ED N- and L-type calcium channel antagonist improves glomerular dynamics, reverse severe nephrosclerosis, and inhibits apoptosis and proliferation in an I-NAME/SHR model J Hypertens 2002 20 5 993 1000 12011661
   PubMed Web of Science ®Google Scholar
• Tsuchihashi T Ueno M Tominaga M Anti-proteinuric effect of an N-type calcium channel blocker, cilnidipine Clin Exp Hypertens 2005 27 8 583 591 16303635
   PubMed Web of Science ®Google Scholar
• Kojima S Shida M Yokoyama H Comparison between cilnidipine and amlodipine besilate with respect to proteinuria in hypertensive patients with renal diseases Hypertens Res 2004 27 6 379 385 15253102
   PubMed Web of Science ®Google Scholar
• Konda T Enomoto A Matsushita J Takahara A Moriyama T The N- and L-type calcium channel blocker cilnidipine suppresses renal injury in dahl rats fed a high-sucrose diet, an experimental model of metabolic syndrome Nephron Physiol 2005 101 1 p1 p13 15886499
   PubMedGoogle Scholar
• Konda T Enomoto A Aritomi S Different effects of L/N-type and L-type calcium channel blockers on the renin-angiotensin-aldosterone system in SHR/Izm Am J Nephrol 2009 30 2 155 161 19325231
   PubMed Web of Science ®Google Scholar
• Takahara A Nakamura Y Wagatsuma H Long-term blockade of L/N-type Ca(2+) channels by cilnidipine ameliorates repolarization abnormality of the canine hypertrophied heart Br J Pharmacol 2009 158 5 1366 1374 19785655
   PubMed Web of Science ®Google Scholar
• Fournier A Oprisiu-Fournier R Serot JM Prevention of dementia by antihypertensive drugs: how AT1-receptor-blockers and dihydropyridines better prevent dementia in hypertensive patients than thiazides and ACE-inhibitors Expert Rev Neurother 2009 9 9 1413 1431 19769454
   PubMed Web of Science ®Google Scholar
• Aritomi S Wagatsuma H Numata T Expression of N-type calcium channels in human adrenocortical cells and their contribution to corticosteroid synthesis Hypertens Res 2011 34 2 193 201 20981032
   PubMed Web of Science ®Google Scholar
• Aritomi S Niinuma K Ogawa T Konda T Nitta K Effects of an N-type calcium antagonist on angiotensin II-renin feedback Am J Nephrol 2011 33 2 168 175 21293118
   PubMed Web of Science ®Google Scholar
• Konoshita T Makino Y Kimura T Genomic Disease Outcome Consortium Study Investigators A new-generation N/L-type calcium channel blocker leads to less activation of the renin-angiotensin system compared with conventional L type calcium channel blocker J Hypertens 2010 28 10 2156 2160 20625317
   PubMed Web of Science ®Google Scholar
• Aritomi S Koganei H Wagatsuma H The N-type and L-type calcium channel blocker cilnidipine suppresses renal injury in Dahl rats fed a high-salt diet Heart Vessels 2010 25 6 549 555 20922532
   PubMed Web of Science ®Google Scholar
• Gress TW Nieto FJ Shahar E Wofford MR Brancati FL Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study N Engl J Med 2000 342 13 905 912 10738048
   PubMed Web of Science ®Google Scholar
• Hsu CY McCulloch CE Darbinian J Go AS Iribarren C Elevated blood pressure and risk of end-stage renal disease in subjects without baseline kidney disease Arch Intern Med 2005 165 8 923 928 15851645
   PubMedGoogle Scholar
• Japanese Society of Hypertension Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2004) Hypertens Res 2006 29 Suppl S1 S105 17366911
   PubMed Web of Science ®Google Scholar
• Fukuzawa Y Watanabe Y Inaguma D Hotta N Evaluation of glomerular lesion and abnormal urinary findings in OLETF rats resulting from a long-term diabetic state J Lab Clin Med 1996 128 6 568 578 8960640
   PubMed Web of Science ®Google Scholar
• Makino N Sasaki M Maeda T Mimori K Telomere biology in cardiovascular disease – role of insulin sensitivity in diabetic hearts Exp Clin Cardiol 2010 15 4 e128 e133 21264070
   PubMedGoogle Scholar
• Aritomi S Niinuma K Ogawa T Konda T Nitta K Additive effects of cilnidipine and angiotensin II receptor blocker in preventing the progression of diabetic nephropathy in diabetic spontaneously hypertensive rats Clin Exp Nephrol 2013 17 1 41 50 23011292
   PubMed Web of Science ®Google Scholar
• van den Born BJ Koopmans RP van Montfrans GA The renin-angiotensin system in malignant hypertension revisited: plasma renin activity, microangiopathic hemolysis, and renal failure in malignant hypertension Am J Hypertens 2007 20 8 900 906 17679041
   PubMed Web of Science ®Google Scholar
• Sechi LA Novello M Colussi G Relationship of plasma renin with a prothrombotic state in hypertension: relevance for organ damage Am J Hypertens 2008 21 12 1347 1353 18948960
   PubMed Web of Science ®Google Scholar
• Rump LC Secondary rise of albuminuria under AT1-receptor blockade – what is the potential role of aldosterone escape? Nephrol Dial Transplant 2007 22 1 5 8 17023493
   PubMed Web of Science ®Google Scholar
• Strauss MH Hall AS Angiotensin receptor blockers may increase risk of myocardial infarction: unraveling the ARB-MI paradox Circulation 2006 114 8 838 854 16923768
   PubMed Web of Science ®Google Scholar
• Furumatsu Y Nagasawa Y Tomida K Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker Hypertens Res 2008 31 1 59 67 18360019
   PubMed Web of Science ®Google Scholar
• Klar J Sigl M Obermayer B Schweda F Krämer BK Kurtz A Calcium inhibits renin gene expression by transcriptional and posttranscriptional mechanisms Hypertension 2005 46 6 1340 1346 16286572
   PubMed Web of Science ®Google Scholar
• Riche DM Minor DS Holdiness AS East HE An issue of dependence: implications from the Aliskiren in the Evaluation of Proteinuria in Diabetes (AVOID) trial J Clin Hypertens (Greenwich) 2009 11 2 89 93 19222674
   PubMed Web of Science ®Google Scholar
• Kaneshiro Y Ichihara A Sakoda M Kurauchi A Takemitsu T Itoh H Cilnidipine and telmisartan similarly improves vascular damage in hypertensive patients Clin Med Insights Cardiol 2007 1 1 11
   Google Scholar
• Blankestijn PJ Rupp H Clinical profile of eprosartan: a different angiotensin II receptor blocker Cardiovasc Hematol Agents Med Chem 2008 6 4 253 257 18855637
   PubMedGoogle Scholar
• Aguilera G Role of angiotensin II receptor subtypes on the regulation of aldosterone secretion in the adrenal glomerulosa zone in the rat Mol Cell Endocrinol 1992 90 1 53 60 1338730
   PubMed Web of Science ®Google Scholar
• Reid AC Mackins CJ Seyedi N Levi R Silver RB Coupling of angiotensin II AT1 receptors to neuronal NHE activity and carrier-mediated norepinephrine release in myocardial ischemia Am J Physiol Heart Circ Physiol 2004 286 4 H1448 H1454 14684374
   PubMed Web of Science ®Google Scholar
• Batlle D Jose Soler M Ye M ACE2 and diabetes: ACE of ACEs? Diabetes 2010 59 12 2994 2996 21115782
   PubMed Web of Science ®Google Scholar
• Zucker IH Schultz HD Patel KP Wang W Gao L Regulation of central angiotensin type 1 receptors and sympathetic outflow in heart failure Am J Physiol Heart Circ Physiol 2009 297 5 H1557 H1566 19717736
   PubMed Web of Science ®Google Scholar
• Kar S Gao L Zucker IH Exercise training normalizes ACE and ACE2 in the brain of rabbits with pacing-induced heart failure J Appl Physiol (1985) 2010 108 4 923 932 20093667
   PubMed Web of Science ®Google Scholar
• Yamamuro M Yoshimura M Nakayama M Aldosterone, but not angiotensin II, reduces angiotensin converting enzyme 2 gene expression levels in cultured neonatal rat cardiomyocytes Circ J 2008 72 8 1346 1350 18654024
   PubMed Web of Science ®Google Scholar
• Aritomi S Niinuma K Kawakami M Cilnidipine, an L-/N-type calcium channel blocker, changes the circulating angiotensin–(1–7)/angiotensin II ratio J Hypertens 2012 1 1 102
   Google Scholar
• Fan YY Kobori H Nakano D Aberrant activation of the intrarenal renin-angiotensin system in the developing kidneys of type 2 diabetic rats Horm Metab Res 2013 45 5 338 343 23322513
   PubMed Web of Science ®Google Scholar